You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-L1 Antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Shanghai, China
    Zhongshan hospital, Fudan University
Aug 12, 2023

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced

Recruiting
  • Esophageal Neoplasms
  • an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Apr 21, 2022

Oesophageal Squamous Cell Carcinoma Trial in Shanghai (PD-L1 Antibody SHR-1316)

Recruiting
  • Oesophageal Squamous Cell Carcinoma
  • PD-L1 Antibody SHR-1316
  • Shanghai, China
    180 Fenglin Road
Jun 12, 2022

Unresectable Hepatocellular Carcinoma Trial (Huaier granule, Atezolizumab + Bevacizumab, Camrelizumab+Apatinib)

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
  • Huaier granule
  • +3 more
  • (no location specified)
Dec 20, 2022

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Molecular Subtyping of Extensive Stage Small Cell Lung Cancer

Recruiting
  • SCLC,Extensive Stage
  • PD-(L)1 antibody immunotherapy
  • Beijing, Beijing, China
    Peking University Cancer Hospital & Institute
Jul 3, 2023

HIV Trial (ASC22 group)

Not yet recruiting
  • HIV Infections
  • ASC22 group
  • (no location specified)
Mar 4, 2022

Advanced Urothelial Carcinoma Trial in Beijing (anti-PD-L1 antibody, albumin bound paclitaxel)

Active, not recruiting
  • Advanced Urothelial Carcinoma
  • anti-PD-L1 antibody
  • albumin bound paclitaxel
  • Beijing, Beijing, China
    Beijing Tumor Hospital
Jan 20, 2022

Chronic Hepatitis b Trial in Beijing (ASC22, sodium chloride)

Active, not recruiting
  • Chronic Hepatitis b
  • Beijing, China
    Peking University First Hospital
Jul 18, 2022

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Cancer Trial in United States (SRK-181, anti-PD-(L)1 antibody therapy)

Recruiting
  • Cancer
  • SRK-181
  • anti-PD-(L)1 antibody therapy
  • Fullerton, California
  • +13 more
Jan 6, 2023

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

SCLC,Extensive Stage, SLFN11-positive Trial in Worldwide (Niraparib)

Not yet recruiting
  • SCLC,Extensive Stage
  • SLFN11-positive
  • Angers, France
  • +19 more
Jan 30, 2023

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE
  • +8 more
  • Quanzhou, Fujian, China
  • +3 more
Jan 29, 2023

Head Neck Cancer Trial in Beijin (anti-PD-1 or PD-L1 antibody, postoperative radiaotherapy)

Recruiting
  • Head and Neck Cancer
  • anti-PD-1 or PD-L1 antibody
  • postoperative radiaotherapy
  • Beijin, Beijing, China
    National Cancer Center /National Clinical Research Center for Ca
Mar 18, 2023

Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

Recruiting
  • Advanced Lung Carcinoma
  • LK101 injection (personlized neoantigen pulsed DC vaccine )
  • +2 more
  • Beijing, Beijing, China
    Cancer hospital Chinese Academy of Medical Sciences
May 23, 2023

PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • L-DEP and PD-1 antibody
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 8, 2023

Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

Recruiting
  • Melanoma (Skin)
  • +4 more
  • Bloomington, Minnesota
  • +7 more
Jan 31, 2023

Envafolimab Combined With Endostar and Concurrent

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
May 19, 2023

NSCLC Trial (BGB-A445, Docetaxel, Tislelizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • (no location specified)
Sep 6, 2023

Biliary Tract Cancer Trial in Shanghai (ZKAB001 5mg/kg, Capecitabine)

Enrolling by invitation
  • Biliary Tract Cancer
  • Shanghai, China
    Renji Hospital Affiliated to School of Medicine, Shanghai Jiaoto
Jan 10, 2022

Solid Tumor, Lymphoma Trial in Beijing (HG146, PD-(L)1 antibody)

Recruiting
  • Solid Tumor
  • Lymphoma
  • Beijing, China
    National Cancer Center/Cancer Hospital
Mar 16, 2022

Advanced or Metastatic Solid Tumors Trial in Kawasaki, Tokyo (KN035)

Completed
  • Advanced or Metastatic Solid Tumors
  • Kawasaki, Japan
  • +1 more
Feb 7, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody
  • Duarte, California
    City of Hope Medical Center
Mar 3, 2022